brianajackson / iStockphoto.com
The English High Court has ruled in favour of Fujifilm Kyowa Kirin Biologics in a case against AbbVie, granting Fujifilm an Arrow declaration allowing it to market a biosimilar of AbbVie’s Humira (adalimumab), a medication used to treat arthritis.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
English High Court, Arrow declaration, AbbVie, Fujifilm, patent, Humira, adalimumab, biosimilar
